Compare Johnson & Johnson (JNJ) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs VF Corp — how do they compare? Johnson & Johnson trades at $250.16 (market cap $598.96B), while VF Corp trades at $16.6 (market cap $6.62B). The key difference: Johnson & Johnson is far larger — about 90.5× VF Corp's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | VFC | |
|---|---|---|
Market Cap | $598.96B | $6.62B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $21.55 |
52-Week Low | $164.36 | $11.66 |
Enterprise Value | $631.90B | $10.77B |
Dividend Yield | 2.15% | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
VFC trades at $16.78, down 1.18% on the day, with technical indicators showing a neutral to bearish short-term bias. The company reported mixed quarterly results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, with revenue declining to $9.50 billion in 2025. Analyst sentiment is cautiously optimistic with a consensus price target of $19.33, while recent news highlights ongoing brand challenges and debt reduction efforts.
The outlook for VFC hinges on execution of its turnaround strategy, particularly revitalizing the Vans brand. Near-term catalysts include Q2 2026 earnings and continued debt management, but risks remain from weak consumer spending and competitive pressures. The stock offers potential upside to analyst targets if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
